Abstract:A subset of cardiomyocytes acquires a senescence‐associated secretory phenotype (SASP) when subjected to doxorubicin (Dox). SASP cardiomyocytes affect healthy non‐senescent cardiomyocytes, rendering them senescent through delivery of exosomes. Clearance of senescent cardiomyocytes using the Bcl‐2 inhibitor ABT‐199 alleviates senescence of cardiomyocytes and prevents chemotherapy‐related cardiotoxicity. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐related cardiotoxicity and could be a new therapeutic target for Dox‐induced cardiac injury. Doxorubicin (Dox), an anthracycline antibiotic, is widely used in cancer treatment. Although its antitumor efficacy appears significant, its clinical use is greatly restricted by its induction of cardiotoxicity. Cardiac senescence drives the Dox‐induced cardiotoxicity, but whether diminishing these senescent cardiomyocytes could alleviate the cardiotoxicity remains unclear. Here, we assessed whether senescent cardiomyocytes have a senescence‐associated secretory phenotype (SASP) that affects healthy non‐senescent cardiomyocytes, rendering them senescent via the delivery of exosomes. Additionally, we explored whether targeting SASP senescent cardiomyocytes using a Bcl‐2 inhibitor could alleviate cardiotoxicity. Cardiac damage was induced in a mouse model of continuous Dox treatment in vivo, and cardiomyocytes in vitro. Immunofluorescence of the senescence markers of Cdkn2a, Cdkn1a and γ‐H2A.X was used to assess the SASP in the Dox‐treated heart. To explore the molecular mechanisms involved, the Bcl‐2 inhibitor ABT‐199 was employed to eliminate SASP senescent cardiomyocytes. We show that the cardiomyocytes acquire a SASP during Dox treatment. The senescent cardiomyocytes upregulated Bcl‐2, although treatment of mice with ABT‐199 selectively eliminated SASP senescent cardiomyocytes involved in Dox‐induced cardiotoxicity, thus leading to partial alleviation of Dox‐induced cardiotoxicity. Moreover, we concluded that SASP factors secreted by senescent cardiomyocytes induced by Dox renders otherwise healthy cardiomyocytes senescent through exosome delivery. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐dependent cardiotoxicity and indicate that targeting the clearance of SASP senescent cardiomyocytes could be a new therapeutic approach for Dox‐induced cardiac injury.

Substance P prevents doxorubicin‐induced cardiomyocyte injury by regulating apoptosis and autophagy: In vitro and in vivo evidence

Spexin inhibits excessive autophagy-induced ferroptosis to alleviate doxorubicin-induced cardiotoxicity by upregulating Beclin 1

Substance P Attenuates Hypoxia/Reoxygenation-Induced Apoptosis Via the Akt Signalling Pathway and the NK1-Receptor in H9C2Cells

Sphingosylphosphorylcholine ameliorates doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by reducing excessive mitophagy and mitochondrial dysfunction

Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance

Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity

Sfrp1 Protects H9c2 Cardiac Myoblasts from Doxorubicin-Induced Apoptosis by Inhibiting the Wnt/PCP-JNK Pathway

Gp130-mediated STAT3 Activation by S-propargyl-cysteine, an Endogenous Hydrogen Sulfide Initiator, Prevents Doxorubicin-Induced Cardiotoxicity

Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunction in mice.

Targeting Heat Shock Protein 47 Alleviated Doxorubicin-Induced Cardiotoxicity and Remodeling in Mice Through Suppression of the NLRP3 Inflammasome.

NADPH oxidase 2 inhibitor GSK2795039 prevents doxorubicin-induced cardiac atrophy by attenuating cardiac sympathetic nerve terminal abnormalities and myocyte autophagy

Anthocyanins from Purple Sweet Potato Alleviate Doxorubicin-Induced Cardiotoxicity in Vitro and in Vivo.

Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress

Saikosaponin D Alleviates DOX-induced Cardiac Injury In Vivo and In Vitro

Astragalus Polysaccharide Restores Autophagic Flux and Improves Cardiomyocyte Function in Doxorubicin-Induced Cardiotoxicity

Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress

Low‐intensity Pulsed Ultrasound Alleviates Doxorubicin‐induced Cardiotoxicity Via Inhibition of S100a8/a9‐mediated Cardiac Recruitment of Neutrophils

Leucine zipper protein 1 prevents doxorubicin-induced cardiotoxicity in mice

Scutellarin Attenuates Doxorubicin‐Induced Cardiotoxicity by Inhibiting Myocardial Fibrosis, Apoptosis and Autophagy in Rats

The SPATA2/CYLD pathway contributes to doxorubicin-induced cardiomyocyte ferroptosis via enhancing ferritinophagy

Peptidomics Analysis Reveals Peptide PDCryab1 Inhibits Doxorubicin-Induced Cardiotoxicity